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Tuberculosis (TB) is an infectious disease caused mainly
by the bacillus Mycobacterium tuberculosis. The World
Health Organization estimates that 8.6 million new TB
cases occurred in 2012, resulting in 1.3 million deaths [1].
TB is the second leading cause of death caused by an
infectious disease worldwide after immunodeficiency virus
(HIV). Despite the availability of an effective chemother-
apy and a moderately protective Bacille-Calmette-Guérin
(BCG) vaccine, TB remains a major global health problem
[1]. BCG provides efficient protection against TB in new-
borns, but its efficacy against the establishment of latent
or pulmonary TB in adults is highly variable. The variabil-
ity of BCG protection in adults might be related to the
absence of more than a hundred genes when compared
with the Mycobacterium bovis pathogenic strain. Among
the missing genes in BCG is the RD1 region which
encodes potent antigens and virulence factors [2]. Thus,
there is an urgent need for the emergence of new prophy-
lactic strategies to decrease TB incidence worldwide. The
development of genetic tools to manipulate mycobacteria
and the completion of M. tuberculosis genome sequencing
have been contributing to a better understanding of genes
involved in TB virulence and pathogenesis, and conse-
quently to the emergence of novel vaccine candidates.
Two major strategies have been used to develop new
vaccine candidates against TB: (i) substitution of BCG in
which an improved version of BCG or a new attenuated
live M. tuberculosis vaccine would have a higher efficiency
than BCG and replace it as a prime vaccine; and (ii) a
prime-boost strategy in which BCG continues to be given
to neonates, and a new vaccine is given as a booster dose
to extend the protection and efficacy [1]. Following these
approaches, numerous vaccine candidates against TB
are currently in preclinical and clinical trials, including
recombinant BCGs, attenuated M. tuberculosis strains,
recombinant viral-vectored platforms, protein/adjuvants
combinations and mycobacterial extracts [1]. The strategy
to develop novel vaccines based on the construction of
rationally attenuated M. tuberculosis strains holds the
advantage of potentially eliciting a more sustained protec-
tive immune response than viral vectored and recombi-
nant protein candidates.
The successful isolation of allelic exchange mutants of
M. tuberculosis is dependent on the ability of the genetic
tools to enable the efficient detection and selection of
mutants among the total population of transformants [3].
Suicide and conditionally-replicating delivery plasmids
that combines both selectable and counter-selectable mar-
kers, reporter gene, and a mycobacterial thermosensitive
origin of replication have been widely used to demonstrate
attenuation of M. tuberculosis mutant strains [3].
The first step towards the development of a new live vac-
cine candidate against TB is the evaluation of mutant strain
attenuation followed by the investigation of its ability to
generate an immune response. Live vaccine candidates
have to mimic natural infection as closely as possible with-
out causing disease, in which, a right balance between
attenuation and immunogenicity has to be reached, since
over attenuated bacteria may not produce in vivo some key
antigens for the induction of a protective immunity [4].
An efficient strategy to rationally attenuate M. tubercu-
losis consists on the construction of double-deletion
mutant of M. tuberculosis in the panC and panD genes,
both involved in the de novo biosynthesis of pantothenate.
Pantothenic acid (vitamin B5) is an essential molecule
required for the synthesis of coenzyme A and acyl carrier
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protein (ACP), two important molecules in fatty acid
metabolism and other metabolic reactions [5]. The dou-
ble-deletion mutant resulted in an auxotrophic and atte-
nuated strain which conferred protection in mice
challenged with virulent M. tuberculosis [5]. In attempts to
further enhance the safety of this live attenuated M. tuber-
culosis vaccine candidate, two other mutant strains were
constructed combining panCD deletion with either lysA
or leuD deletions, involved in lysine and leucine biosynth-
esis, respectively. The mc26020 strain, constructed by the
inactivation of the panCD and lysA genes, is strictly auxo-
trophic for pantothenate and lysine, severely attenuated
and capable of inducing protective responses against an
aerosolized M. tuberculosis challenge in both immuno-
competent and immunocompromised mice [6]. The strain
constructed by inactivation of the panCD and leuD genes
was shown to confer long-term protection against chal-
lenge with virulent M. tuberculosis in guinea pig model
which is equivalent to that afforded by BCG [7]. Simian
immunodeficiency virus (SIV)-positive and SIV-negative
Rhesus macaques were immunized with panCD and leuD
mutant strain, and safety studies, clinical, hematological
and bacteriological monitoring were carried out and
revealed no vaccine-associated adverse effects [7].
Another successful approach employed to rationally
attenuate M. tuberculosis combines deletions in secA2 and
lysA genes. The secA2 gene encodes a component of a
virulence-associated bacterial protein secretion system
involved in inhibiting the host immune system and conse-
quently promoting the M. tuberculosis survival within the
host. Thus, secA2 mutant was shown to increase both host
cell apoptosis and priming of antigen-specific CD8+ T
cells in vivo. The secA2 and lysA double-mutant strain
retained the effects obtained by secA2 single mutation, but
with an improved safety profile in immunosuppressed
mice [8].
Recently, the first live-attenuated M. tuberculosis-based
vaccine, MTBVAC, entered clinical trials. MTBVAC con-
tains in two independent deletions without antibiotic-resis-
tance markers in the genes phoP, coding for a transcription
factor key for the regulation of M. tuberculosis virulence,
and fadD26, coding for one of the major mycobacterial
virulence factors [9]. First, a mutant strain containing a sin-
gle mutation in phoP gene was constructed and showed a
high degree of safety, improved immunogenicity and pro-
tective efficacy compared to BCG in several animal models,
from mice to non-human primates. Then, a second inde-
pendent mutation deleting fadD26 gene was introduced to
obtain MTBVAC which was shown to be functionally and
phenotypically comparable to its prototype after rigorous
preclinical safety and biodistribution experiments [9]. This
vaccine candidate was genetically engineered to fulfill the
Geneva consensus requirements for Phase I clinical trials
of live mycobacterial vaccines candidates which demands
improved protective efficacy and safety potential relative to
BCG, and two non-reverting independent mutations with-
out antibiotic resistance markers [10].
Overall, these multiple deletion mutants demonstrated
the feasibility to obtain rationally attenuated M. tuberculo-
sis strains, which so far were shown to be safe without
compromising their ability to provide protective immunity,
making them viable live vaccines candidates against TB.
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